Abiopharma

🔍 Tan Kevin (Executive)

Company: Solid Biosciences Inc. (SLDB)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 11,250 shares of Common Stock (Direct)
  Date: 2026-01-09 | Code: M | equity_swap_involved: false | shares_owned_after: 51,804.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,704 shares of Common Stock at $5.27 per share (Direct)
  Date: 2026-01-13 | Code: S | equity_swap_involved: false | shares_owned_after: 46,100.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 11,250 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-09 | Code: M | equity_swap_involved: false | shares_owned_after: 11,250.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Restricted stock units convert to common stock on a one-for-one basis.
• F2: Includes 4,152 and 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025 and November 28, 2025, respectively.
• F3: This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.
• F4: The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.